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Mutations in DVL1 Cause
an Osteosclerotic Form of Robinow Syndrome
Kieran J. Bunn,1,7 Phil Daniel,1,7 Heleen S. Ro¨sken,1 Adam C. O’Neill,1 Sophia R. Cameron-Christie,1
Tim Morgan,1 Han G. Brunner,2,3 Angeline Lai,4 Henricus P.M. Kunst,5 David M. Markie,6
and Stephen P. Robertson1,*
Robinow syndrome (RS) is a phenotypically and genetically heterogeneous condition that can be caused bymutations in genes encoding
components of the non-canonical Wnt signaling pathway. In contrast, germline mutations that act to increase canonical Wnt signaling
lead to distinctive osteosclerotic phenotypes. Here, we identified de novo frameshift mutations in DVL1, a mediator of both canonical
and non-canonical Wnt signaling, as the cause of RS-OS, an RS subtype involving osteosclerosis, in three unrelated individuals. The mu-
tations all delete the DVL1 C terminus and replace it, in each instance, with a novel, highly basic sequence. We showed the presence of
mutant transcript in fibroblasts from one individual with RS-OS and demonstrated unimpaired protein stability with transfected GFP-
tagged constructs bearing a frameshift mutation. In vitro TOPFlash assays, in apparent contradiction to the osteosclerotic phenotype,
revealed that the mutant allele was less active than the wild-type allele in the canonical Wnt signaling pathway. However, when the
mutant and wild-type alleles were co-expressed, canonical Wnt activity was 2-fold higher than that in the wild-type construct alone.
This work establishes that DVL1 mutations cause a specific RS subtype, RS-OS, and that the osteosclerosis associated with this subtype
might be the result of an interaction between the wild-type and mutant alleles and thus lead to elevated canonical Wnt signaling.Robinow syndrome (RS [dominant RS, MIM 180700; reces-
sive RS, MIM 268310]) is a genetically and phenotypically
heterogeneous skeletal dysplasia characterized by the
distinctive facial appearance of midface hypoplasia, hyper-
telorism, a short nose, and a broad mouth, known collec-
tively as ‘‘fetal facies.’’ Additional but variable features of
RS include mesomelic dwarfism, macrocephaly, gingival
hypertrophy, dental malocclusion, genital hypoplasia, bra-
chydactyly, bifid thumbs, and segmentation defects (re-
viewed in Mazzeu et al.1).
Some forms of RS are caused by mutations in genes en-
coding components of Wnt signaling pathways.2–4 Wnt
signaling is a complex pleiotropic network for which
more than 19 Wnt ligands and more than 15 Wnt recep-
tors and co-receptors have been described.5 Signaling via
these complexes is broadly divided into canonical and
non-canonical pathways. Activation of the canonical
pathway byWnt ligands prevents the degradation of b-cat-
enin, which accumulates in the cytoplasm and moves to
the nucleus to alter gene expression.5 Germline mutations
in the canonical pathway in humans cause a number of de-
fects, the most notable of which is an impact upon bone
mineral density (BMD). A high-bone-mass phenotype
(MIM 144750) is caused by gain-of-function mutations in
LRP5 (MIM 603506),6,7 whereas a reduction in expression
or activity of the extracellular soluble Wnt antagonist
SOST (MIM 605740) leads to van Buchem disease (MIM
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The Aman increase in canonical Wnt signaling will cause an in-
crease in bone mass, and the converse, is well established
through a number of other human10–12 and animal13,14
studies (reviewed in Wang et al.15).
Non-canonical Wnt signaling is more mechanistically
heterogeneous in that it involves a number of interrelated
signaling cascades. Germline mutations in genes encod-
ing components of one particular non-canonical Wnt
signaling pathway, termed the planar cell polarity (PCP)-
Wnt pathway, cause some forms of RS.2–4
RS has both dominantly and recessively inherited forms,
which differ both by their phenotype and by their mode of
inheritance.1 Recessive RS, characterized by severe meso-
melia and segmentation defects such as hemivertebrae or
rib fusions, is caused by biallelic loss-of-function muta-
tions in the gene encoding the transmembrane Wnt co-re-
ceptor ROR2 (receptor tyrosine kinase-like orphan receptor
2).2,3 In a small minority of individuals with dominant RS,
characterized by a milder phenotype without rib fusions,
the condition is caused by loss-of-function mutations in
the gene encoding the classical PCP-Wnt ligand Wnt-5a.4
No other mutations have previously been associated with
human RS.
It is well known that there is substantial cross-talk be-
tween the canonical and non-canonical pathways (re-
viewed in Niehrs5). Despite this, there is no indication
that the Mendelian conditions discussed above have im-
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Figure 1. Clinical Presentation of and
Mutations in RS-OS
(A–G) Clinical features of RS-OS.
(A and B) Facial appearance of subject 1.
Note the midface hypoplasia, flat facial
profile, hypertelorism, and broad mouth.
(C) Transverse CT of subject 1. Note the
pronounced osteosclerosis of the cranial
vault.
(D) Appearance of the hands of subject 2.
Note the the camptodactyly and brachy-
dactyly.
(E) Lateral X-ray of the skull of subject 2.
Note the thickened calvarium and in-
creased bone density.
(F) X-ray of the left hand, wrist, and forearm
of subject 1. Note the osteosclerosis in the
cortices of the long bones of the forearm
and the camptodactyly, clinodactyly, and
bifid thumb. (This image was reproduced
with permission from Bunn et al.17)
(G) X-ray of the left hand, wrist, and forearm of subject 1. Note the cortical osteosclerosis of the forearm and the
camptodactyly, clinodactyly, and bifid thumb (less obvious than in subject 1).
(H) DVL1 mutations leading to RS-OS.
(I) DVL1 structure showing exons. The arrow indicates exon 14, the location of the three mutations.
(J) An illustration of DVL1 shows the similarity among the altered proteins and their difference from the wild-type. The shaded box in-
dicates the novel shared C-terminal sequence.number of Wnt mediators are shared components of both
canonical and non-canonical signaling—the dishevelled
family of proteins (DVL) is the primary example.16
Three unrelated individuals with the clinical diagnosis of
sporadic RS with atypical dramatic osteosclerosis (RS-OS)
were ascertained and described previously (Figures 1A–
1G).17,18 These individuals exhibited a clinical presenta-
tion of dominant RS with characteristic facial dysmor-
phism (marked hypertelorism, short nose, broad mouth,
and midface hypoplasia), camptodactyly and brachydac-
tyly (in subjects 1 and 2), cleft palate (in subjects 2 and
3), and dental anomalies. Mesomelia, another common
finding in RS, ranged frommild to absent in these individ-
uals, but this observation does not preclude a clinical diag-
nosis of RS.19 Radiographs revealed osteosclerosis of the
cranium, which was particularly prominent at the skull
base (Figure 1E). In subjects 1 and 2, generalized axial
and appendicular osteosclerosis was also documented
and was particularly marked in the cortices of the long
bones, which were also undertubulated (Figures 1F and
1G). No information on the remainder of the skeleton
was available for individual 3. In subjects 1 and 2, the distal
phalanges of the hands and feet were hypoplastic, and the
terminal phalanx of the thumb was bifid, a pattern typical
of RS.20 Dual-energy X-ray absorptiometry scanning of the
skeleton revealed markedly elevated BMD (lumbar spine Z
scores were þ7.4 for subject 1 and þ7.6 for subject 2). The
parents of all three individuals were clinically unremark-
able. Table 1 summarizes these clinical features.
Elevated BMD occurring in the context of sporadic RS
in three unrelated individuals of different ethnic back-
grounds and without relevant family history, consanguin-
ity, or sibling recurrence led us to hypothesize that this
phenotype was underpinned by rare de novo mutations624 The American Journal of Human Genetics 96, 623–630, April 2, 2at a previously unidentified locus. All subjects participated
after informed consent was obtained in keeping with the
principles of the Declaration of Helsinki. Ethical approval
for this work was obtained from the Southern Health and
Disability Ethics Committee of New Zealand (reference
no. 13/STH/56). Accordingly, we performed whole-exome
sequencing and employed a parent-proband-trio design
to identify de novo variants in subject 1. DNA was ex-
tracted from blood leukocytes and captured with an
Agilent SureSelect All Exon V4 Kit and sequenced on an
Illumina HiSeq2000 with paired-end 100-bp reads. Data
were processed for alignment, and variants were called ac-
cording to the current best-practice guidelines from the
Broad Institute.21 Reads were aligned to the human
genome (GRCh37) with the Burrows-Wheeler Aligner
(BWA)-MEM,22 base quality scores were recalibrated with
the Genome Analysis Toolkit (GATK), and variants were
called with the GATK HaplotypeCaller. Each exome had
an average read depth of >303. Variants were annotated
with SnpEff,23 and SnpSift was used to identify de novo
mutations in subject 1.24 Novelty was determined by the
exclusion of variants identified in 400 in-house exomes
and of variants found in the NHLBI Exome Sequencing
Project Exome Variant Server (ESP6500). Variants were
filtered for quality and for a read depth of >53 across the
trio. Annotation with SnpEff was used to filter for effects
likely to disrupt protein sequences. All apparently de
novo single-base substitutions and small insertions or dele-
tions were validated by Sanger sequencing of the parents
and proband.
Two coding variants, a frameshift (c.1519del
[p.Trp507Glyfs*142]; RefSeq accession number NM_
004421.2) inDVL1 (MIM 601365) and a single-base substi-
tution (c.2753C>T [p.Pro918Leu]; RefSeq NM_014494.2)015
Table 1. Clinical and Radiographic Features of the Three Subjects
with RS-OS
Subject 1 Subject 2 Subject 3
Hypertelorism þ þ þ
Mesomelia   
Cleft palate  þ þ
Camptodactyly and
brachydactyly
þ þ 
Gingival hyperplasia þ þ 
Oligodontia þ þ þ
Bilateral mixed hearing loss þ þ þ
Osteosclerosis of skull þ þ þ
Osteosclerosis of long bones þ þ NA
Bifid thumb and great toe þ þ NA
Abbreviations are as follows: þ, present; , absent; NA, information not
available.in TNRC6A (MIM 610739), satisfied these criteria as the
only functional de novo mutations found in this individ-
ual. TNRC6A encodes a component of a cytoplasmic ribo-
nucleoprotein complex that regulates mRNA silencing,
stability, and translation. PolyPhen-2,25 which uses phys-
ical properties and evolutionary conservation to predict
deleterious effects of coding variants, predicted that the
p.Pro918Leu substitution is likely to be benign. No novel
sequence variants in TNRC6A were observed in subject 2.
DVL1 is a central mediator of Wnt signal transduction.
The c.1519del frameshift falls within the penultimate
exon of the 15-exon DVL1. This mutation is predicted to
remove almost the entirety of the C-terminal tail of DVL1
and replace this sequence with a 142-amino-acid-long,
novel, highly basic sequence (the predicted pI of the C-ter-
minal section rises from9.5 to 12.526). Direct sequencing of
the relevant exons and intron-exon boundaries ofDVL1 in
individuals 2 and 3 identified two similar de novo frame-
shift mutations in DVL1: c.1562del (p.Pro521Hisfs*128)
and c.1576_1583delinsG (p.Pro526Alafs*121), respec-
tively. Each DVL1 mutation leads to a frameshift in the
same reading frame.All threeDVL1mutations arepredicted
to lead to a protein product 23 residues shorter than wild-
type DVL1 (Figures 1H–1J). The same novel C-terminal
sequence, which ranges from 121 to 142 residues in length
and differs only in the extent of its N terminus, is predicted
to be appended to the DVL1 proteins produced from these
mutant alleles (Figures 1I and 1J).
DVL proteins are widely conserved Wnt signaling medi-
ators throughout evolution.27 Mammals have three DVL1
paralogs (DVL1–DVL3), all of which share a high level of
sequence homology. They encode intracellular scaffolding
proteins acting directly downstream from the transmem-
brane Wnt receptors (frizzled family). At DVL, the Wnt
pathways functionally diverge into the canonical and
non-canonical cascades; which way they diverge is depen-
dent upon which downstream mediators DVL interactsThe Amwith (reviewed in Gao and Chen16). The three DVL paral-
ogs have separate but overlapping roles, which are
elegantly shown in a series of mouse knockouts.28 Of the
three Dvl knockouts, loss of Dvl1 has the least phenotypic
impact; null mice display no dysmorphic phenotype.29 In
contrast, Dvl2-null mice have cardiac, segmentation, and
neural-tube defects.30 Dvl3-null mice show pathologies
similar to those of Dvl2-null mice, and additional cochlear
anomalies, and rarely survive until adulthood.31 DVL pro-
teins have three well-defined functional domains: the
N-terminal DIX (dishevelled and axin), the PDZ (postsyn-
aptic density 95, disc large, and zonula occludens 1), and
the C-terminal DEP (dishevelled, Egl-10, and pleckstrin)
domains (Figure 1J). To date, no mutations at any of the
DVL loci have been associated with clinically apparent
defects in human Wnt signaling.
The three clustered mutations in the individuals des-
cribed in this study fall outside the three established do-
mains of DVL and thus introduce C-terminal frameshifts
after the DEP domain. However, a number of conserved
C-terminal regions, including sites that are subject to phos-
phorylation,32 binding sites for ubiquitin ligases,33–35 and
enzymes that mediate DVL degradation,36 are predicted to
be removed by these mutations. Additionally, the muta-
tions delete a site necessary for the function of a deubiqui-
tination enzyme,37 the binding site for IQGAP1 (which
controls DVL nuclear localization38), and a frizzled inter-
acting domain.39Considering the lack of malformations
in Dvl1/ mice, the lack of phenotypic effects similar
to RS-OS in individuals with deletions encompassing
DVL1,40 and our observation that all three frameshift mu-
tations replace functional domains with the same, highly
basic novel C terminus, these DVL1 alleles seem to confer
the RS-OS phenotype by a specific mechanism distinct
from simple haploinsufficiency. Thus, the focus of this
work was to understand the mechanistic basis of the osteo-
sclerotic aspect of the RS-OS phenotype, given that osteo-
sclerosis is the main phenotypic feature that differentiates
these individuals from other subjects with RS.
The three DVL1 mutations all occur within a confined
region of DVL1 and could be acting through either a loss
or gain of function. All three fall in the penultimate
exon, where the novel reading frame does not encounter
a premature stop codon before entering the last exon (Fig-
ures 1I and 1J). This observation presents the possibility
that these mutation-bearing transcripts could escape
nonsense-mediated decay (NMD). To investigate, we pre-
pared cDNA from dermal fibroblasts obtained from subject
1 and performed RT-PCR to amplify a product that
spanned parts of exons 14 and 15, including the site of
the mutation. After this product was sequenced, both
mutant and wild-type alleles were observed on the Sanger
chromatogram, suggesting that the mutant allele was not
subject to NMD (data not shown). To confirm this, we di-
gested these same RT-PCR products with BstN1, which spe-
cifically cuts at a site that is destroyed by the mutation. A
substantial proportion of the product derived from theerican Journal of Human Genetics 96, 623–630, April 2, 2015 625
Figure 2. Expression and Localization of
Frameshifted and Truncated DVL1
(A) The DVL1 PCR product was digested
with the restriction enzyme BstN1 for
4 hr at 60C. The digest shows the presence
of mutant transcript (which is refractory to
digestion) alongside wild-type transcript
in fibroblasts obtained from subject 1.
(B) Chemiluminescent immunoblot of
C2C12 cells (40,000/well) transiently trans-
fected (0.6 ml/well of Lipofectamine2000,
Life Technologies) with EGFP-tagged
DVL1 constructs (100 ng/well,incubated
for 24hr) demonstrates comparable protein
levels (anti-GFP, A6455, Life Technologies;
anti-GAPDH, G8795, Sigma). Note the size
difference between the truncated DVL and
the other constructs.
(C–F) Representative images from fluores-
cent microscopy of C2C12 cells transiently
transfected with EGFP or the EGFP-DVL1 constructs (100 ng/well) show that p.Trp507* DVL1 (shDVL1) andmtDVL1 retain the ability to
form puncta. shDVL1 is a construct that leads to a truncated protein terminating at the site of the frameshift mutation (c.1519insTAA
[p.Trp507*]) found in subject 1.subject-1 cDNA was refractory to digestion, whereas a con-
trol was digested to completion (Figure 2A).
To ascertain whether the frameshift-containing protein
produced from the c.1519del allele found in individual 1
demonstrated significant instability, we performed an
immunoblot on skin fibroblast lysate, but this failed to
detect DVL1 in either subject or control cultures. To
circumvent this inability to detect endogenous DVL1,
we cloned an N-terminal GFP-tagged full-length DVL1
construct (GFP-wtDVL1) and introduced the c.1519del mu-
tation by site-directed mutagenesis (GFP-mtDVL1). This
clone was transfected into C2C12 cells, and immunodetec-
tion was performedwith anti-GFP antibodies with band in-
tensities normalized to endogenous GAPDH. These results
indicated no apparent difference in abundance between
the altered and wild-type DVL1 (Figure 2B). This was
confirmed by infrared immunofluorescence, normalized
to a-tubulin (n¼ 3; Figure S1). These data indicate thatmu-
tation-bearing alleles that lead to RS-OS are transcribed and
translated into stable proteins and consequently hold the
potential to exert novel biological functions or interfere
with endogenous DVL1-mediated activities.
Previous work has found that loss of the DVL1 C termi-
nus reduces the protein’s ability to signal in the canonical
Wnt pathway and is mediated by either a loss of interac-
tion with the frizzled receptor39 or a deubiquitinating
enzyme.37 The osteosclerosis observed in the three RS-
OS-affected individuals studied here is phenotypically
reminiscent of a LRP6-related high-bone-mass phenotype,
van Buchem disease, and sclerosteosis, which are all caused
by increases in canonicalWnt signaling, albeit via differing
mechanisms.6–9,41 We reasoned that, although previous
genes linked to RS signal through the PCP-Wnt pathway,
DVL1 mediates both canonical and PCP-Wnt signaling,
leaving open the possibility that the osteosclerotic aspects
of the RS-OS phenotype could be caused by a defect in the
canonical pathway. We therefore investigated the impact626 The American Journal of Human Genetics 96, 623–630, April 2, 2of one of theDVL1mutations on signaling through the ca-
nonical Wnt pathway.
We employed a transient transfection system utilizing
the TOPFlash reporter42 to investigate the impact of the
DVLI mutation on canonical Wnt signaling. This tran-
scriptional reporter is composed of three b-catenin-respon-
sive TCF promoter elements driving firefly luciferase gene
transcription.42 C2C12 cells were transfected with plas-
mids containing different forms of DVL1: wild-type
DVL1 (wtDVL1), a construct containing the variant found
in subject 1 (c.1519del [p.Trp507Glyfs*142];mtDVL1), and
a short form encoding a protein truncated at the site
affected by the frameshift mutation in individual 1
(c.1519insTAA [p.Trp507*]; shDVL1). We used the last
construct to investigate any detectable differences between
the activity of DVL1 proteins without the wild-type C ter-
minus and the activity of the proteins that had C termini
but were encoded by the frameshifted sequence that was
30 to each of the three mutations.
Typically, wild-type DVL1 oligomerizes to form focal
puncta in cells.43 The ability to form supramolecular com-
plexes (seen as puncta) is a necessary property for canoni-
cal Wnt signaling.43,44 We therefore questioned whether
the truncated or frameshifted DVL1 proteins demon-
strated altered subcellular distribution in comparison to
that of wild-type proteins. C2C12 cells were transfected
with constructs specifying N-terminal, GFP-tagged ver-
sions of each DVL1 variant. Fluorescent microscopy of
transfected cells yielded a punctate pattern of expression
and no evident differences among frameshifted, truncated,
and wild-type proteins (Figures 2D–2F).
Increasing amounts of untagged constructs were trans-
fected into C2C12 cells, and after an overnight incubation,
their impact on canonical signaling was measured through
TOPFlash activation (Figure 3A). Transfection of wtDVL1
led canonical Wnt activity to increase up to 29-fold (at
32 ng/well) higher than that of an empty vector control.015
Figure 3. Impact of DVL1 Constructs on Canonical Wnt
Signaling
(A) TOPFlash reporter assay in C2C12 cells. Cells were transiently
transfected with 80 ng/well of TOPFlash reporter, 20 ng/well of a
constitutively active b-galactosidase construct, and a variable
amount of a DVL1 construct and incubated for 18 hr. Combined
luciferase activities of three independent experiments normalized
to the b-galactosidase activity are depicted and reported as a
relative increase over that of an empty vector (n ¼ 3). Error bars
represent the SEM. Log-transformed two-way ANOVA found a sig-
nificant difference between the mutant and every other construct
(p < 0.001). Individual p values were calculated with Tukey HSD
tests and denote the difference between mtDVL1 and every other
construct.
(B) C2C12 cells were transiently transfected with a fixed amount
of eachDVL1 construct (4 ng/well) or with a 1:1 stoichiometric ra-
tio of two constructs with the same total amount of DVL1 and
incubated for 18 hr. The same reporters and processing were
used as above, and the luciferase activity is expressed as a propor-
tion of the wtDVL1 activation (n ¼ 5). Error bars represent
the SEM. P values were calculated with Tukey HSD tests (*p 0.05,
**p ¼ 0.01, ***p ¼ 0.001).Consistent with the previously published data, the shDVL1
construct was less potent in increasing signaling activity:
at high levels of expression, the DVL1 DC terminus was
less active in the canonical pathway than full-length
wtDVL1.37,39 The mtDVL1 construct only raised signaling
activity to a maximum level of 3-fold higher than that
of empty vector controls. A log-transformed two-way
ANOVA found that there was a significant difference be-
tween the mtDVL1 construct and the other two constructsThe Am(p < 0.001). The most remarkable and unanticipated
finding from these data was the substantially reduced ac-
tivity of the mtDVL1 construct. These results are in
apparent conflict with the hypothesis that the osteoscler-
otic phenotype of individuals with RS-OS is attributable
to over-activity in the canonical Wnt pathway.
To further investigate this issue, we focused on the stim-
ulatory capabilities of these constructs at lower levels of
transfection because the concentrations of transfected
plasmid that yielded maximal stimulation in the forego-
ing experiments are unlikely to reflect physiological con-
centrations of DVL1 either in vivo or in C2C12 cells,
which are known to express this gene.45 Given that the
individuals studied here are heterozygous for the dis-
ease-causing mutation and therefore express a wtDVL1
allele in trans with the mutant, we hypothesized that a
stoichiometric balance between these two alleles would
more closely reflect the in vivo context. We co-transfected
mtDVL1 and wtDVL1 in a 1:1 ratio while maintaining the
same total amount of DVL1 as each construct alone (4 ng/
well). A similar 1:1 ratio of shDVL1:wtDVL1 was also
examined under the same conditions. After a 24-hr incu-
bation, the mtDVL1:wtDVL1 co-transfection elevated ca-
nonical activity to 2-fold higher than that of wtDVL1
alone. A significant difference was found between the
mtDVL1:wtDVL1 combination and all other constructs
and construct combinations (p < 0.01, Tukey honest
significant difference (HSD) tests; Figure 3B). This same
pattern was also found in the presence of a Wnt stimulus
in the form of Wnt-3a-conditioned media (Figure S2).
These experiments suggest that the protein produced by
this frameshift mutation, which results in RS-OS, exerts
a stimulatory effect on canonical Wnt signaling when it
is co-expressed with the wild-type protein. This stimula-
tory activity was not evident, even at supraphysiological
levels of expression, when mtDVL1 was transfected alone.
Furthermore, the statistical difference between co-trans-
fections of shDVL1:wtDVL1 and mtDVL1:wtDVL1 also
suggests that the stimulatory effect of the mtDVL1 allele
is not solely attributable to the truncation of the C termi-
nus of DVL1.
The components in common between the RS-OS
phenotype and other forms of RS are also likely to relate
to perturbations in Wnt signaling. Mutations in effectors
of PCP-Wnt signaling, such as ROR2 and WNT5A, lead to
RS phenotypes2–4 but do not lead to florid alterations in
BMD, such as those described here. DVL1 is common to
all described Wnt signaling receptor complexes, and so it
is plausible that a deficiency in its action within the PCP-
Wnt pathway could lead to the RS components of the
RS-OS phenotype. A possible mediator of this effect might
be the DVL-interacting protein PRICKLE1, which has been
shown to bind the C-terminal half of DVL.46 Loss of
Prickle1 disrupts the PCP-Wnt-induced DVL gradient in
mice and Drosophila,46,47 and mice with hypomorphic
Prickle1 alleles appear phenotypically similar to mice
with RS.47erican Journal of Human Genetics 96, 623–630, April 2, 2015 627
The mechanism by which canonical Wnt signaling is
upregulated in amanner that is dependent on the presence
of a wild-type allele is unresolved. A truncation of even just
the final 16 C-terminal residues of DVL1 reduces canonical
Wnt signaling as a result of a weaker affinity for the Wnt
receptor frizzled.39 The C terminus also contains binding
sites for a deubiquitination enzyme required to activate
DVL, and specific mutagenesis of residues mediating this
interaction also reduces canonical Wnt activity.37 Addi-
tionally, a DVL construct that lacked the native C terminus
failed to interact with IQGAP1, a protein that facilitates
canonical Wnt signaling by controlling DVL nuclear local-
ization.38 These proposed mechanisms perhaps explain
the observed reductions of in vitro activity at high
levels of expression (Figure 3A) but conflict with the RS-
OS osteosclerotic phenotype, which suggests that canoni-
cal signaling is elevated.
A partial explanation might relate to the effect of
the loss of the wild-type C terminus on the stability
of DVL1. The C terminus of DVL1 contains a number of
proline-rich clusters that are deleted by the frameshift
mutations leading to RS-OS. These regions bind the E3
ubiquitin ligases HECW1 (previously known as NEDL1),
ITCH, and NEDD4L, which mediate the degradation of
DVL.33–35 Additionally, guanine nucleotide-binding pro-
tein b2 (Gb2) interacts with the DEP-C region of DVL
(some of which is deleted by these mutations) to degrade
DVL.36 ITCH, NEDD4L, and Gb2 have been directly shown
to inhibit canonical Wnt activity through their interac-
tion with DVL.34–36 This is, however, insufficient to fully
explain our observations given that a high level of
mtDVL1 dramatically underperformed in comparison to
the wtDVL1 construct in our TOPFlash transfection assays
(Figure 3A). Simply an increase in stability, and thus
amount, of DVL1 is insufficient to explain the RS-OS
phenotype.
Phosphorylation of DVL, which requires key Ser and Thr
residues in the C terminus, negatively regulates canonical
Wnt signaling.32 The phosphorylated DVL disrupts the
formation of DVL puncta,48 which we have shown can
still be formed by p.Trp507Glyfs*142 DVL1 (mtDVL1)
(Figures 2D–2F) and are essential for b-catenin-dependent
signaling.44 Thus, the absence of these key sites in the
altered proteins might lend a resistance to phosphoryla-
tion and thus stabilize these signaling puncta. Our obser-
vation of a significant difference between the activity of
mtDVL1 and shDVL1, both at high expression and in trans
with wtDVL1 (Figure 3B), suggests that the novel, highly
basic, C-terminal region introduced by all three mutant al-
leles lends additional influence to the signaling capabilities
of these protein complexes.
This report adds to the genetic heterogeneity of RS and
places mutations in DVL1 alongside those in ROR2 and
WNT5A as causative of a subtype of the disorder, RS-OS.
The biochemical mechanisms behind this phenotype
remain largely mysterious; however, the mutations re-
ported in this study appear to simultaneously affect both628 The American Journal of Human Genetics 96, 623–630, April 2, 2canonical and PCP-Wnt signaling pathways. The nature
of the impact upon the canonical Wnt pathway is partially
explained by this work, and intriguingly, the effect seems
to be mediated by the co-expression of both mutant and
wild-type alleles, suggesting that these mutations exert
their effects through an interaction with wild-type DVL
within the Wnt signalosome.Supplemental Data
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